Ryan Fukushima Sells 2,868 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 2,868 shares of Tempus AI stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $81.87, for a total transaction of $234,803.16. Following the completion of the sale, the chief operating officer now directly owns 944,460 shares of the company’s stock, valued at approximately $77,322,940.20. The trade was a 0.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, February 4th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $62.50, for a total transaction of $1,250,000.00.
• On Tuesday, January 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $39.61, for a total transaction of $792,200.00.
• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The shares were sold at an average price of $40.23, for a total transaction of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The stock was sold at an average price of $42.51, for a total value of $5,101,200.00.

Tempus AI Price Performance

TEM opened at $68.09 on Friday. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $91.45. The company’s 50-day moving average price is $50.29 and its two-hundred day moving average price is $51.65. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Hedge Funds Weigh In On Tempus AI

Institutional investors have recently bought and sold shares of the company. Operose Advisors LLC purchased a new stake in Tempus AI during the fourth quarter valued at about $25,000. First Horizon Advisors Inc. bought a new stake in shares of Tempus AI in the third quarter valued at approximately $30,000. Farther Finance Advisors LLC purchased a new stake in shares of Tempus AI during the 4th quarter valued at approximately $34,000. Prestige Wealth Management Group LLC lifted its stake in shares of Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after buying an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC bought a new position in Tempus AI in the 4th quarter worth approximately $49,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

TEM has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a research report on Tuesday, January 14th. Wolfe Research initiated coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Bank of America boosted their price target on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. TD Cowen reiterated a “buy” rating and issued a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Finally, William Blair cut shares of Tempus AI from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 12th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.